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The exact molecular mechanism by which epigallocatechin gallate (EGCG) suppresses human pancreatic cancer cell proliferation
is unclear. We show here that EGCG-treated pancreatic cancer cells AsPC-1 and BxPC-3 decrease cell adhesion ability on micro-
pattern dots, accompanied by dephosphorylations of both focal adhesion kinase (FAK) and insulin-like growth factor-1 receptor
(IGF-1R) whereas retained the activations of mitogen-activated protein kinase and mammalian target of rapamycin. The growth
of AsPC-1 and BxPC-3 cells can be signiﬁcantly suppressed by EGCG treatment alone in a dose-dependent manner. At a dose of
100μM which completely abolishes activations of FAK and IGF-1R, EGCG suppresses more than 50% of cell proliferation without
evidence of apoptosis analyzed by PARP cleavage. Finally, the MEK1/2 inhibitor U0126 enhances growth-suppressive eﬀect of
EGCG. Our data suggests that blocking FAK and IGF-1R by EGCG could prove valuable for targeted therapy, which can be used
in combination with other therapies, for pancreatic cancer.
1.Introduction
Worldwide pancreatic cancer is associated with high mor-
bidity, estimated to cause 213,000 deaths annually [1].
Due to late clinical presentation, rapid tumor progression,
andresistance to conventional chemotherapeutic agents, the
5-year survival rate remains less than 5%. The hope for
patients with pancreatic cancer comes from an improved
understanding of the molecular mechanism underlying the
highly aggressive nature of this disease, providing more
selective methods for an eﬀective treatment.
Focal adhesion kinase (FAK) is a nonreceptor cytoplas-
mic tyrosine kinase that plays an important role in several
diﬀerent cell processes including cell proliferation, migra-
tion, and survival [2]. The activation of FAK requires
autophosphorylation of residue tyrosine 397, upon ligand
binding and clustering of intergrin receptors, as well as
activation of other cell surface receptors such as EGFR [3].
Importantly, FAK is overexpressed in cancers and inhibition
of FAK activity sensitizes cancer cells to apoptosis [4],
suggesting that FAK plays a role in carcinogenesis. Very
recently, Liu et al. have shown that FAK and insulin-
like growth factor 1 receptor (IGF-1R) interact to provide
survival signals in pancreatic cancer cells [5]. IGF-1R is one
of the major receptor tyrosine kinases to trigger several key
molecules for cell proliferation and survival. Overexpression2 Journal of Biomedicine and Biotechnology
of IGF-1R has been detected in many diﬀerent types of
cancers including pancreatic cancer [6, 7], making it a
potential target for therapy. Indeed, inhibition of IGF-1R
by a small molecule kinase inhibitor NVP-AEW541 reduced
pancreatic tumor growth [8]. Moreover, TAE226, a novel
dual tyrosine kinase inhibitor for FAK and IGF-1R, exhibited
anticancer eﬀect in esophageal adenocarcinoma [9]a sw e l l
as in glioma [10]. In the present study, we have shown
for the ﬁrst time that epigalocatechin galate (EGCG) from
natural green tea eﬀectively inhibited phosphorylations of
both FAK and IGF-1R in human pancreatic cancer cell
lines AsPC-1 and BxPC-3, accompanied by suppression of
cell adhesion and proliferation. At a dose of 100μM that
already abolished activations of FAK and IGF-1R, EGCG
had no eﬀect on either phosphorylations of two major
signal transduction pathways believed to play key roles in
carcinogenesis, mitogen-activated protein kinase (MAPK)
and mammalian target of rapamycin (mTOR), or in causing
apoptosis by PARP cleavage analysis. Importantly, MAPK
inhibitorenhancesEGCG-inducedantiproliferativeresponse
in cancer cells.
2.MaterialsandMethods
2.1. Cell Lines and Culture Conditions. The human pancre-
atic cancer cell lines AsPC-1 and BxPC-3, obtained from
ATCC (American Type Culture Collection, Manassas, VA,
USA), were grown in RPMI supplemented with 10% fetal
bovine serum (FBS; JRH Biosciences, Lenexa, KS, USA),
100U/ml penicillin, and 0.1mg/ml streptomycin (Nacalai
Tesque, Tokyo, Japan) in a humidiﬁed incubator of 5% CO2
at 37◦C.
2.2. Fabrication of Octadecylsilane Pattern for the Evaluation
of Cell Adhesion. For evaluating the cell adhesion quanti-
tatively, a two-tone organosilane monolayer pattern com-
posed of cell-adhesive region and cell-repellent region was
fabricated on glass slides using electron beam lithography.
Chemical vapor deposition (CVD) of tetraethylorthosilicate
(TEOS) was performed to ﬂatten the Pyrex glass slide. A
dual-layer photopolymer ﬁlm was spin-coated and patterned
into an array of 15μm diameter circles by electron beam
lithography. The glass slide was then exposed to a vapor of n-
octadecyltrimethoxysilane (ODS) at 110◦C. By removing the
photopolymer ﬁlm in tetrahydrofuran (THF), the array of
holes were formed in the ODS monolayer. After cleaning the
glasssubstratebysonicatinginchloroformandinethanolfor
10 minutes each, the glass surface exposed within the holes
was selectively modiﬁed with 3-aminopropyltriethoxysilane
(APTES) by immersing the glass substrate in a solution of
2% APTES in 95% ethanol/water for 30 minutes. Prior to
cell culture, the glass slide was sterilized by immersing the
substrate in 70% ethanol/water for 10 minutes and rinsing
in water twice. As previously reported [11], bovine serum
albumin (BSA) adsorbed selectively on the ODS monolayer
surface prevented the cells from adhering to outside the
circles, while the surface modiﬁed with APTES prompted the
cells to attach to the circles. Thus the cell attachment
is limited within the 15μm diameter circles modiﬁed with
APTES.
AsPC-1 and BxPC-3 cells were plated at a density of
0.8×105 cells/ml in the presence or absence of EGCG onto
micropatterncoverslipsfor24hours.Cellsattachingtosingle
dots were photographed under microscope.
2.3. Reagents. A puriﬁed preparation of EGCG was gen-
erously provided by Dr. Yukihiko Hara, Mitsui-Norin
(Shizuoka, Japan). U0126 (MEK1/2 inhibitor) was pur-
chased from Cell Signaling Technology (Danvers, MA, USA).
EGCG and U0126 were dissolved in dimethylsulfoxide
(DMSO). The concentration of DMSO was kept under 0.1%
throughout all the experiments to avoid its cytotoxicity.
2.4. Proliferation Assays. For measurement of cell prolifer-
ation, cells were seeded in quadruplicate in 96-well plates,
in 100μl of culture media in the presence of various
concentrations of EGCG. After incubation for 48 hours,
10μl of TetraColor ONE reagent containing tetrazolium
monosodium salt (Seikagaku Corporation, Tokyo, Japan)
was added to each well and cells were incubated for
additional4hours.Absorbanceat450nmwasmeasuredwith
the Biotrack II plate reader (Amersham Biosciences, Uppsia,
Sweden). Results were enumerated as the percentage of the
v a l u e sm e a s u r e dw h e nc e l l sw e r eg r o w ni nt h ea b s e n c eo f
EGCG.
For trypan blue exclusion assay, cells were plated in 24-
well dishes with diﬀerent concentrations of EGCG for 48
hours, harvested with a brief incubation in 0.05% trypsin
and 0.02% EDTA, stained with trypan, blue and counted
manually using a hemacytometer.
2.5.WesternBlotAnalysis. Cellswereplatedonto6-cmdishes
at a density of 2×105 cells/ml in the presence of various
concentrations of EGCG. After incubation for indicated
times,cellswerecollectedbytrypsinizationandwashedtwice
inphosphate-buﬀeredsaline(PBS).Cellswerethendissolved
in a protein lysis buﬀer containing 5mM EDTA, 50mMNaF,
10mM Na2H2P2O7, 0.01% Triton X-100, 5mM HEPES,
150mM NaCl, 1mM Na3VO4, 1mM phenylmethylsulfonyl
ﬂuoride, and 75μg/mL aprotinin on ice for 30 minutes
with brief vortex every 10 minutes. After centrifugation at
13,000rpm at 4◦C for 10 minutes, total cell lysates were
collected for western blot analysis as described previously
[12].
The following antibodies were obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA): N-cadherin
(sc-7939), FAK (sc-557), IGF-IRβ (sc-713), ERK1 (sc-
93), antirabbit IgG- HRP (sc-2317), and antimouse IgG-
HRP (sc-2031). Antiactin (A2066) was from Sigma (Saint
Louis, MO, USA). Phospho-IGF-I-receptor β (Tyr1131),
phospho-p44/42Mapkinase(Thr202/Tyr204),phospho-Akt
(Ser473), phospho-mTOR (Ser2448), caspase-3, caspase-8,
and caspase-9 antibodies were from Cell Signaling Tech-
nology. Phospho-FAK (pTyr397) was from ABR Aﬃnity
Bioreagents (Golden, CO, USA). Anti-E-cadherin was from
BD Biosciences (San Jose, CA, USA). Anti-PARP was fromJournal of Biomedicine and Biotechnology 3
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Figure 1: EGCG suppresses cell adhesion by micropattern assay. AsPC-1and BxPC-3 cells were plated at a density of 0.8× 105 cells/ml in the
presence of indicated doses of EGCG onto micropattern coverslips as described in the Materials and Methods. After 24 hours, cells attaching
to single dots were photographed under microscope.
WAKO Chemicals (Osaka, Japan). Alexa ﬂuor 488 goat
antirabbit secondary antibody was from Molecular Probes
(Eugene, OR, USA).
2.6. Immunoﬂuorescence Staining and Confocal Microscopy.
Cells were plated at a density of 0.8×105 cells/ml onto
coverslips and allowed to attach for 24 hours. After being
treated with 100μM EGCG for 6 hours, cells were ﬁxed
in 4% paraformaldehyde for 10 minutes and permeabilized
with 0.1% Triton X in PBS for 5 minutes. Cells were then
washed with PBS, blocked with 2% bovine serum albumin
for 30 minutes, and incubated with p-FAK antibody for 1
hour at room temperature. After washing three times with
0.05% Triton X in PBS, cells were subsequently incubated
with Alexa ﬂuor 488 goat antirabbit secondary antibody for
1 hour at room temperature, and nuclei were stained with
Topro 3 before mounting. The slides were viewed using a
Zeiss LSM 510 laser confocal microscope (Carl Zeiss, Jena,
Germany).
3. Results
3.1. EGCG Suppresses Cell Adhesion on Micropattern Dots.
Cell adhesion to other cells or extracellular matrix is of great
importance in the development and disease of multicellular
organisms. We developed a micropatterned substrate where
adhesion of single cells can be observed in order to quantify
the eﬀect of EGCG on cell-adhesion capacity (Figure 1).
In the absence of EGCG, at a density of 0.8×105 cells/ml,
approximately 60% of dots were occupied with single cells.
Cell adhesion was signiﬁcantly reduced at 40μME G C G
(approximately 20% of dots were occupied with single cells),
and nearly abolished at 80μM EGCG.
3.2. EGCG Inhibits FAK and IGF-IR Activations and the
Expression of Target Molecule N-Cadherin in Pancreatic
Carcinoma Cells. To understand the molecular mechanism
responsible for suppression of cell adhesion by EGCG, we
ﬁrst examine the phosphorylation status of FAK, a key
player in cell adhesion [13]. As shown in Figure 2(a),F A K
was constitutively activated in pancreatic cancer cells, albeit
with lower level in AsPC-1 cells than in BxPC-3 cells.
EGCG at 100μM completely abolished phosphorylation of
FAK in both cell lines, while expression of total FAK was
unchanged. In BxPC-3 cells, which harbor high level of
activatedFAK,EGCGinhibitsthephosphorylationofFAKin
a dose-dependent manner (Figure 2(a)). In consistency with
western blot results, confocal microscopy analyses conﬁrm
that EGCG blocks FAK activation in pancreatic cancer cells
(Figure 2(b)).
Because tyrosine phosphorylation of FAK was reported
necessary for the interaction of FAK and insulin-like growth
factor 1 receptor (IGF-1R) that was important for survival
signals in pancreatic cancer cells [5], we next evaluate
phosphorylation status of IGF-1R by western blot analysis.
Quite similar to FAK, IGF-1R was strongly phosphorylated
in BxPC-3 cells, and lower level of phosphorylation was
observed in AsPC-1 cells (Figure 2(a)). As expected, 100μM
EGCG was enough to abolish phosphorylation of IGF-1R in
both cell lines, whereas it had no eﬀect on expression of total
IGF-1R. Furthermore, IGF-1R became reactivated at the 20-
hour time point when EGCG concentration in culture might4 Journal of Biomedicine and Biotechnology
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Figure 2: EGCG inhibits FAK activity. (a) Cells were plated at a density of 2×105 cells/ml in the presence of various concentrations of
EGCG for 12 hours, except for BxPC-3 at 100μM for additional 4 or 8 hours. Total cell lysates were subjected to western blot analysis
with indicated antibodies. Cells cultured in medium with 0.1% DMSO were used as a control. (b) Immunoﬂuorescence staining for p-FAK
(green) in BxPC-3 cells in the absence or presence of 100μM EGCG, as indicated. Expression of p-FAK (arrows) was signiﬁcantly reduced
in EGCG-treated cells as compared with control cells. Staining with TOPRO-3 (red) visualizes the nuclei.
be decreased so much, indicating that the eﬀect of EGCG on
activation of IGF-1R is reversible (Figure 2(a)).
Since FAK upregulates N-cadherin expression in pan-
creatic cancer cells through p130CAS [14], we ask whether
inhibition of FAK by EGCG can downregulate N-cadherin
expression. As shown in Figure 2(a), BxPC-3 cells, but not
AsPC-1 cells, express N-cadherin. In consistency with FAK
activity, N-cadherin expression is abrogated in BxPC-3 cells
treated with 100μM EGCG.
3.3. Inhibition of FAK and IGF-IR Activity by EGCG
Suppresses Cell Growth in Pancreatic Carcinoma Cells. To
determine whether inhibition of FAK and IGF-IR activity
by EGCG would lead to cell growth inhibition, TetraColor
ONE cell proliferation assays were performed. As shown in
Figure 3(a), EGCG inhibited the cell proliferation in a dose-
dependent manner, with an IC50 value of approximately
72μMa n d6 4 μM for AsPC-1 cells and BxPC-3 cells,
respectively.Resultswereconﬁrmedbytrypanblueexclusion
assay (data not shown). Under microscope, we also observed
that, at low density, all cancer cells were killed by EGCG
at 100μM after 48 hours (data not shown). However,
as shown in Figure 3(b), the cell growth inhibition by
EGCGdiminisheddramaticallywithincreasingcelldensities,
similar to phenomena reported in colorectal carcinoma cells
[15]. It is noteworthy that at a density of approximately
2×105 cells/ml, EGCG at 100μM is able to suppress more
than 50% cell growth (Figure 3(b)) and abolish phos-
phorylation of FAK and IGF-1R as well as N-cadherinJournal of Biomedicine and Biotechnology 5
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Figure 3: EGCG suppresses cell proliferation. (a) AsPC-1 and BxPC-3 cells at a density of 0.8×105 cells/ml were seeded in quadruplicate
in 96-well plates, in 100μl of culture media in the presence of various concentrations of EGCG. After incubation for 48 hours, 10μlo f
TetraColor ONE reagent was added to each well, and cells were incubated for additional 4 hours. Absorbance at 450 nm was measured
with the Biotrack II plate reader. Results were enumerated as the percentage of the values measured when cells were grown in the absence of
EGCG.(b)CellproliferationassaysforBxPC-3cellsatdiﬀerentcelldensities.Valueswereobtainedfromexperimentsconductedintriplicate.
(c) EGCG fails to cause apoptosis in AsPC-1 and BxPC-3 cells. Cells were plated at a density of 2 × 105 cells/ml in the presence or absence of
100μM EGCG for 12 hours followed by western blot analysis of total cell lysates using indicated antibodies. MIAPaCa-2 cells were used as a
control of apoptosis induced by EGCG.
expression (Figures 2(a) and 2(b)), but fails to cleave PARP,
a sign of caspase-dependent apoptosis, in AsPC-1 and BxPC-
3 cells (Figure 3(c)). In EGCG-treated BxPC-3 cells, nuclear
integrity but not any apoptotic nuclear alterations [16]w a s
visualizedbyTOPRO-3staining(Figure 2(b)).Incontrast,in
MIAPaCa-2 cells used as a control, EGCG induces apoptosis
with cleaved PARP accompanied by cleaved caspase 8 [17].
Our results are in consistency with data from Qanungo’s
study where MIAPaCa-2 cells were sensitive, whereas BxPC-
3 cells were moderately responsive and AsPC-3 cells were
nonresponsive to EGCG-induced PARP cleavage [18].
3.4. MEK1/2 Inhibitor Increases the Antiproliferative Response
to EGCG. Since EGCG exhibits antiproliferative eﬀect in
AsPC-1 and BxPC-3 cells without evidence of caspase-
dependent apoptosis, we suspect that EGCG-treated pancre-
atic cancer cells retain activation of pathways important for
cell survival. As shown in Figure 4(a), EGCG up to 100μM
failstoinhibit phosphorylation ofMAPKandmTORinboth
AsPC-1 and BxPC-3 cells. At ﬁrst, we were confused by the
fact that even though EGCG abolished the phosphorylation
of AKT, which was thought to be the main modulator
of mTOR activation, it had no eﬀect on phosphorylation6 Journal of Biomedicine and Biotechnology
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Figure 4: (A) EGCG fails to inhibit phosphorylation of MAPK and mTOR in AsPC-1 and BxPC-3 cells. Cells were plated at a density of
2×105 cells/ml in the presence of various concentrations of EGCG for 12 hours, except for BxPC-3 at 100μM for additional 4 or 8 hours.
Total cell lysates were subjected to western blot analysis. (b) MAPK inhibitor enhances EGCG-induced antiproliferative response in BxPC-3
cells. Cells were plated at a density of 0.6×105 cells/ml in 24-well dishes with diﬀerent concentrations of EGCG for 48 hours in the presence
or absence of 10μM U0126 (MEK1/2 inhibitor). Cells were detached by trypsin, stained with trypan blue and counted manually using
a hemacytometer. Values were obtained from experiments conducted in triplicate. Asterisk indicates signiﬁcant diﬀerence. Inhibition of
phosphorylation of MAPK by U0126 at 10μM was conﬁrmed with western blot analysis.
of mTOR in AsPC-1 cells (Figure 4(a)); however, very
recently, Stephan et al. have clearly demonstrated that PKCδ
but not AKT acts upstream of mTOR and that mTOR
phosphorylation was PKCδ dependent in AsPC-1 cells [19].
It has been also reported that inhibition of migration in
bladder carcinoma cells associated with AKT but not MAPK
signaling [20].
We next want to know whether inhibition of MAPK
activity by an inhibitor can enhance antiproliferative
response of pancreatic cancer cells to EGCG. As expected,
MAPK inhibitor potentiated the EGCG-induced antipro-
liferative response in BxPC-3 cells (Figure 4(b)). A similar
result was observed in AsPC-1 cells (data not shown).
4. Discussion
Advances in pancreatic carcinogenesis have provided more
novel promising targets for prevention and treatment.
Among them, upregulation of N-cadherin expression plays
a key role in tumor progression and metastasis [21]. EvenJournal of Biomedicine and Biotechnology 7
though it was reported that EGCG downregulated N-
cadherin expression and suppressed migration of bladder
carcinoma cells [20], the molecular mechanism underlying
downregulationofN-cadherinexpressionwasnotaddressed.
Recently,ShintanigrouphavedemonstratedthatFAKupreg-
ulated N-cadherin expression in pancreatic cancer cells [14].
In agreement with their ﬁndings, we have shown here for
the ﬁrst time that EGCG abolished N-cadherin expression
in pancreatic cancer cells via inhibition of FAK activation
(Figure 2). The inhibition was accompanied by blocking
activation of IGF-1R, which interacts with FAK to provide
survival signals in pancreatic cancer cells [5]. Indeed, EGCG
was shown to be a highly potent inhibitor of IGF-1R tyrosine
kinase activity [22]. On the other hand, in human colon
carcinoma cells, inhibition of FAK activity by EGCG was
reported to alter invasive phenotype [23]. We have further
observed inhibition of FAK activity by EGCG in 2 prostate
cancercelllinesPC-3andDU145(datanotshown).Whether
inhibition of FAK by EGCG in pancreatic cancer cells can
actually prevent metastasis requires further animal study.
However, at least, the inhibition of both FAK and IGF-1R
could lead to cell growth inhibition (Figures 3(a) and 3(b)).
The fact that cell growth inhibition depends on cell density,
wherecellpopulationwithlowdensitybutnotthatwithhigh
density could be killed completely by EGCG (Figure 3(b)),
predictsthatmetastasispreventionbyEGCGcanbeachieved
a only if it is used at very early stage, before metastasis has
been set in by large numbers of metastatic cancer cells.
Clinical trials of EGCG in patients with cancers con-
ﬁrmed that the substance was well tolerated and supported
a potential role for EGCG in the treatment and prevention
of cancer [24, 25]. Due to a relatively short half life plus
low oral bioavailability, high concentrations of EGCG are
unattainable in vivo, particularly in plasma, even if people
consume an excess of EGCG. However, it may be feasible
to achieve therapeutic dosages at relatively low dosages of
prodrug Petacetate-EGCG which is readily taken up by
tumor cells and converted to EGCG [26]. In mice, EGCG
might be eﬀectively delivered locally up to 200μMt o
eradicate aggressive, metastatic tumors [27].
With respect to therapeutic aspect, our ﬁndings do
not support the application of EGCG alone for pancreatic
cancer, because of its limited eﬀect on cell growth inhi-
bition, without evidence of apoptosis (Figures 3(b) and
3(c)). Instead, combination of EGCG with other inhibitors
such as MAPK inhibitor should be tested for this dismal
cancer, since MAPK inhibitor enhanced the EGCG-induced
antiproliferative response in cancer cell lines (Figure 4(b)).
We observed that EGCG at 200μM had no signiﬁcant eﬀect
on the healthy human peripheral blood mononuclear cells
and human lung ﬁbroblast cell line WI-38 (data not shown),
indicating speciﬁc toxicity of EGCG towards cancer cells.
Pancreatic cancer is an aggressive disease with aberrant
activations of numerous signaling pathways. Among them,
activation of MAPK by KRAS or BRAF mutation promotes
the survival and growth of cancer cells [28, 29]. A phase I
trial of BAY 43-9006/sorafenib, a speciﬁc inhibitor of RAF, in
combination with gemcitabine for patients with pancreatic
cancer indicated that the therapy was well tolerated [30].
Together, current ﬁndings warrant a combination of MAPK
inhibitor such as sorafenib and EGCG for pancreatic cancer.
This work was presented in the International Conference
on the Development of Biomedical Engineering in Viet-
nam [31].
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